E
TNDM icon

Ergoteles’s Tandem Diabetes Care TNDM Stock Holding History

Ergoteles’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,555
Closed -$684K – 1985
2022
Q2 		$684K Buy
+11,555
New +$949K 0.02% 703
2020
Q4 		– Sell
-6,725
Closed -$763K – 906
2020
Q3 		$763K Buy
+6,725
New +$707K 0.1% 164

Other funds holding TNDM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ergoteles's TNDM Position: Q3 2022 in Review

Ergoteles sold out of Tandem Diabetes Care (TNDM) in Q3 2022, closing a stake of 11,555 shares — an estimated $684K sold.

Ergoteles first reported a position in TNDM in Q3 2020 and held it in 2 quarters. The position peaked at $763K in Q3 2020. 299 funds tracked by Wall St. Rank hold TNDM as of Q3 2022.

  • Ergoteles reported no remaining Tandem Diabetes Care position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 11,555 Tandem Diabetes Care shares in Q3 2022, an estimated $684K.
  • Ergoteles first reported a position in Tandem Diabetes Care in Q3 2020 and held it in 2 quarters.
  • Ergoteles's Tandem Diabetes Care position peaked at $763K in Q3 2020.
  • 299 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.